文献速递炎症性肠病胃肠动力与功能性疾病

静止期炎症性肠病中肠易激综合征样症状的干预:随机试验荟萃分析

Managing Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Meta-Analysis of Randomized Trials.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-26

饮食干预症状改善的合并标准化均数差(SMD)最大(-1.33;95%CI -4.42至1.77;I2=90%),但证据确定性极低;行为干预效应较小(SMD -0.36;95%CI -0.82至0.10;I2=0%),证据确定性低。现有证据不支持任何单一干预类别具有确切获益。

要点

  • 饮食干预症状改善的SMD最大,但异质性高且证据确定性极低。
  • 行为干预显示小效应,证据确定性低,置信区间跨零。
  • 药物和其他干预仅限孤立小样本试验,证据有限。

核心结论

  • 当前证据不支持任何单一干预类别对静止期IBD的IBS样症状具有确切获益。

研究设计与样本

  • 按干预类别(饮食、行为、药物和其他)分别汇总症状严重度和生活质量结局,采用随机效应模型(Hartung-Knapp调整)合并SMD,使用Cochrane RoB 2评估偏倚风险,GRADE评估证据确定性。

主要发现

  • 饮食干预症状改善的合并SMD为-1.33(95%CI -4.42至1.77;I2=90%),证据确定性极低(因异质性和不精确性)。
  • 行为干预的合并SMD为-0.36(95%CI -0.82至0.10;I2=0%),证据确定性低。
  • 药物和其他干预的证据仅限于孤立的小型试验。
  • 53.8%的研究偏倚风险高,主要因缺乏盲法和主观终点。

临床怎么用

  • 现有证据不足以推荐任何单一干预类别作为静止期IBD中IBS样症状的确定性治疗。
  • 临床决策需结合个体情况,并告知患者证据的不确定性。

局限性

  • 纳入研究异质性高(饮食干预I2=90%),证据不精确。
  • 53.8%的研究偏倚风险高,主要因缺乏盲法和使用主观终点。
  • 药物和其他干预的证据仅限于孤立的小型试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Persistent irritable bowel syndrome (IBS)-like symptoms affect up to one-third of patients with inflammatory bowel disease (IBD) in remission, representing a major unmet need not addressed by anti-inflammatory therapies. Despite increasing use of dietary and gut-brain-targeted strategies, their efficacy in this population remains uncertain. We performed a meta-analysis of randomized controlled trials (RCTs) to quantify the therapeutic effects of these interventions. METHODS: We systematically searched PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and ClinicalTrials.gov through October 2025 for RCTs enrolling adults with quiescent IBD and IBS-like symptoms. Interventions were synthesized according to intervention class (dietary, behavioral, pharmacologic, and other), with symptom severity and quality of life outcomes analyzed separately within each class. Standardized mean differences (SMDs) were pooled using random-effects models with Hartung-Knapp adjustment. The risk of bias was assessed using Cochrane Risk of Bias 2 and the certainty of evidence using Grading of Recommendations Assessment, Development, and Evaluation. RESULTS: Thirteen RCTs (n = 688) were included. Dietary interventions demonstrated the largest pooled symptom benefit (standardized mean difference [SMD], -1.33; 95% confidence interval, -4.42 to 1.77; I2 = 90%), although evidence was very low certainty because of heterogeneity and imprecision. Behavioral interventions showed a small treatment effect (SMD, -0.36; 95% confidence interval, -0.82 to 0.10; I2 = 0%) with low-certainty evidence. Evidence for pharmacologic and other interventions was limited to isolated, small trials. The risk of bias was high in 53.8% of studies, driven primarily by lack of blinding and subjective end points. CONCLUSIONS: The current evidence does not support a definitive benefit for any single intervention class in the management of IBS-like symptoms in quiescent IBD. Although dietary interventions demonstrated the largest point estimate for symptom improvement, the evidence remained highly uncertain because of imprecision and risk of bias. Larger, rigorously designed, blinded trials using standardized end points are needed to define effective symptom-directed therapies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Goyal MK, Lee A, Shah D, et al. Managing Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Meta-Analysis of Randomized Trials. Clin Gastroenterol Hepatol. 2026. PMID: 42790835. doi:10.1016/j.cgh.2026.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。